Question 1

What is Viatris's P/E ratio?

Accepted Answer

Viatris (VTRS) P/E ratio is 259.1× as of May 8, 2024. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Viatris?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Viatris specifically, the relevant sector benchmark is the current sector median of 25.0×.

Question 5

Is Viatris's P/E ratio high or low?

Accepted Answer

Viatris's P/E ratio of 259.1× is above its own 5-year average of 46.4× and above the sector median of 25.0×. That places the current reading at the 95th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Viatris's historical P/E ratio range?

Accepted Answer

In the available daily series, Viatris (VTRS) P/E ratio has ranged from a low of 5.3× in 2023 to a high of 617.5× in 2019. The 5-year average is 46.4× and the 5-year median is 9.7×.

Question 7

What was Viatris's P/E ratio in 2023?

Accepted Answer

Viatris (VTRS) P/E ratio at the end of 2023 was 237.6×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Viatris's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$14.35B	−$3.51B	—	—	Dec 31, 2025
2024	$14.86B	−$634.20M	—	—	Dec 31, 2024
2023	$13.00B	$54.70M	237.6×	+231.1×	Dec 31, 2023
2022	$13.59B	$2.08B	6.5×	—	Dec 31, 2022
2021	$16.22B	−$1.27B	—	—	Dec 31, 2021
2020	$16.01B	−$669.90M	—	—	Dec 31, 2020
2019	$10.37B	$16.80M	617.5×	+577.5×	Dec 31, 2019
2018	$14.10B	$352.50M	40.0×	+7.6×	Dec 30, 2018
2017	$22.56B	$696.00M	32.4×	-10.2×	Dec 30, 2017
2016	$20.47B	$480.00M	42.6×	+10.1×	Dec 30, 2016
2015	$27.56B	$847.60M	32.5×	+8.7×	Dec 30, 2015
2014	$22.17B	$929.40M	23.9×	—	Dec 30, 2014


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
UnitedHealth Group (UNH)	20.4×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
HCA Healthcare (HCA)	15.8×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Elevance Health (ELV)	12.3×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Viatris (VTRS)

P/E Ratio daily chart for Viatris (VTRS)

Historical P/E Ratio for Viatris (VTRS) from 2014 to 2025

About P/E Ratio at Viatris (VTRS)

Viatris P/E Ratio by Year

Viatris P/E Ratio 2023: 237.6×

Viatris P/E Ratio 2022: 6.5×

Viatris P/E Ratio 2019: 617.5×

Viatris P/E Ratio 2018: 40.0×

Viatris P/E Ratio 2017: 32.4×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Viatris (VTRS) Key Financials

P/E Ratio daily chart for Viatris (VTRS)

Historical P/E Ratio for Viatris (VTRS) from 2014 to 2025

About P/E Ratio at Viatris (VTRS)

Viatris P/E Ratio by Year

Viatris P/E Ratio 2023: 237.6×

Viatris P/E Ratio 2022: 6.5×

Viatris P/E Ratio 2019: 617.5×

Viatris P/E Ratio 2018: 40.0×

Viatris P/E Ratio 2017: 32.4×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

+What is Viatris's P/E ratio?

+How is the P/E ratio calculated?

+What is the P/E ratio?

+What is a good P/E ratio for Viatris?

+Is Viatris's P/E ratio high or low?

+What is Viatris's historical P/E ratio range?

+What was Viatris's P/E ratio in 2023?

+Why does Viatris's P/E ratio change over time?

Viatris (VTRS) Key Financials